{"id":"fd5648f6-a93c-460e-918c-021449c44e97","name":"Dexcom","slug":"dexcom","description":"Dexcom is an American multinational medical device company pioneering continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, the company's product line includes the Dexcom G6, G7, and Stelo glucose biosensors, with manufacturing facilities in Arizona, Malaysia, and Ireland. Dexcom is publicly traded on Nasdaq (DXCM) and is a component of the S&P 500 and Nasdaq-100.","status":"public (NASDAQ: DXCM)","founded":1999,"hq":"San Diego, California, USA","fundingTotal":"50000000","type":"both","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx","title":"Stelo by Dexcom: first glucose biosensor FDA-cleared OTC (De Novo Mar 5 2024; adults 18+ not on insulin)","sourceName":"Dexcom (investor relations)"},{"url":"https://investors.dexcom.com/news/news-details/2024/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing/default.aspx","title":"Dexcom launches generative-AI platform for Stelo (Google Cloud Vertex AI + Gemini; Weekly Insights)","sourceName":"Dexcom (investor relations)"},{"url":"https://www.medtechdive.com/news/dexcom-gen-ai-feature-stelo-cgm/735918/","title":"Dexcom gen-AI for Stelo (personalized insights; AI photo meal logging)","sourceName":"MedTech Dive"}],"keyFacts":[{"label":"Product","value":"Stelo OTC continuous glucose monitor"},{"label":"Boundary","value":"Glucose-biometric + real AI -> in-definition INCLUDE (not a bare sensor)."},{"label":"wikipedia","value":"https://en.wikipedia.org/wiki/Dexcom"},{"label":"wikidata","value":"https://www.wikidata.org/wiki/Q15109865"},{"label":"CEO","value":"Jacob (Jake) Leach"},{"label":"Listed on","value":"NASDAQ: DXCM"},{"label":"Founders","value":"Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston, Bret Megargel"},{"label":"Employees","value":"11,100 (2025)"},{"label":"Revenue","value":"$4.6B (2025 est), $5.16-5.25B guidance for 2026 (11-13% growth)"},{"label":"Stock","value":"NASDAQ: DXCM"}],"aliases":["DexCom Inc","Stelo"],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"createdAt":"2026-06-03T22:46:45.745Z","updatedAt":"2026-07-18T14:44:18.961Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/dexcom","url":"https://registry.deploy.report/companies/dexcom","name":"Dexcom","alternateName":["DexCom Inc","Stelo"],"description":"Dexcom is an American multinational medical device company pioneering continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, the company's product line includes the Dexcom G6, G7, and Stelo glucose biosensors, with manufacturing facilities in Arizona, Malaysia, and Ireland. Dexcom is publicly traded on Nasdaq (DXCM) and is a component of the S&P 500 and Nasdaq-100.","identifier":["fd5648f6-a93c-460e-918c-021449c44e97",{"@type":"PropertyValue","propertyID":"wikidata","value":"Q15109865"}],"foundingDate":"1999","address":"San Diego, California, USA","sameAs":["https://en.wikipedia.org/wiki/Dexcom","https://www.wikidata.org/wiki/Q15109865"],"publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":3,"primary_source_types":["primary-company-ir","secondary-trade-publication"]}}}